SYDRA utilizes a closed-loop discovery platform that combines artificial neural networks with autonomous robotic in vivo screening to identify novel small molecules with geroprotective properties. The startup aims to develop longevity supplements and anti-aging drugs to combat the biological mechanisms of aging.
Funding
Funding not disclosed
Founders
Product
Problem
The discovery of novel geroprotective compounds, which can promote healthy aging and extend lifespan, is a slow and resource-intensive process. Traditional drug discovery methods often lack the efficiency and scalability needed to thoroughly explore the chemical space for molecules that can effectively target the biological mechanisms of aging.
Solution
SYDRA employs a closed-loop drug discovery platform that integrates artificial intelligence with autonomous robotic in vivo screening to accelerate the identification of novel small molecules with geroprotective properties. The platform uses artificial neural networks to design potential drug candidates, and then automatically tests these candidates in living organisms using a robotic system. This iterative process allows SYDRA to rapidly screen and identify compounds that can modulate aging pathways, with the goal of developing longevity supplements and anti-aging therapeutics. The integration of AI and robotics streamlines the discovery process, reduces development time, and enhances the capacity to find effective geroprotectors.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing interventions for age-related diseases and promoting healthy aging.
Features
- Closed-loop platform combining AI-driven drug design with robotic in vivo screening
- Artificial neural networks tailored for identifying small molecules with geroprotective properties
- Autonomous robotic system for high-throughput screening in living organisms
- Data-driven approach to optimize and accelerate the drug discovery process
- Capability to screen and validate new animal pathology models for aging research